- Home
- BDL vs ACRV Comparison
BDL vs ACRV Comparison
Compare BDL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDL
- ACRV
- Stock Information
- Founded
- BDL 1959
- ACRV 2018
- Country
- BDL United States
- ACRV United States
- Employees
- BDL N/A
- ACRV N/A
- Industry
- BDL Restaurants
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- BDL Consumer Discretionary
- ACRV Health Care
- Exchange
- BDL Nasdaq
- ACRV Nasdaq
- Market Cap
- BDL 52.7M
- ACRV 47.8M
- IPO Year
- BDL N/A
- ACRV 2022
- Fundamental
- Price
- BDL $31.55
- ACRV $1.99
- Analyst Decision
- BDL
- ACRV Buy
- Analyst Count
- BDL 0
- ACRV 6
- Target Price
- BDL N/A
- ACRV $17.75
- AVG Volume (30 Days)
- BDL 2.1K
- ACRV 1.1M
- Earning Date
- BDL 08-12-2025
- ACRV 11-07-2025
- Dividend Yield
- BDL 1.67%
- ACRV N/A
- EPS Growth
- BDL 41.91
- ACRV N/A
- EPS
- BDL 2.32
- ACRV N/A
- Revenue
- BDL $201,851,000.00
- ACRV N/A
- Revenue This Year
- BDL N/A
- ACRV N/A
- Revenue Next Year
- BDL N/A
- ACRV $805.34
- P/E Ratio
- BDL $14.19
- ACRV N/A
- Revenue Growth
- BDL 8.84
- ACRV N/A
- 52 Week Low
- BDL $22.61
- ACRV $1.05
- 52 Week High
- BDL $35.98
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- BDL 59.25
- ACRV 52.67
- Support Level
- BDL $31.00
- ACRV $1.91
- Resistance Level
- BDL $31.97
- ACRV $2.46
- Average True Range (ATR)
- BDL 0.87
- ACRV 0.16
- MACD
- BDL 0.06
- ACRV -0.01
- Stochastic Oscillator
- BDL 79.53
- ACRV 26.49
About BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.